A study was made on 50 cases of epileptic children who had been observed at the pediatric department of Chungnam National University Hospital Taejeon Eul Ji Hospital during the period from July, 1986 to June, 1991. The result are as follows: 1) Epilepsy was most frequent in children from 1 year to 10 year of age (80%). Epilepsy was commoner in female children compare to male representing male to female ratio, 1:1.2. 2) Intractable cases with VPA were 40%, and male to female ratio was 1.2:1. Intractable cases were most common between 1 and 5 years (65%). 3) The most common epileptic type was generalized tonic clonic seizure (38%). 4) The clinical effect of valproic acid was the worst in severely abnormal EEG finding. 5) The mean plasma VPA level was significantly lower for the polytherapy (57.7microgram/ml) than for the monotherapy (69.5microgram/ml). The VPA dose of steady-state was significantly higher for polytherapy (27.9mg/kg/d) than for the monotherapy (20.9mg/kg/d). VPA level: dose ratio was reduced in the polytherapy (2.1) as compared to monotherapy (3.3). 6) The plasma VPA level increased according to dosage. In the same dose, plasma level of monotherapy was significantly higher than polytherapy. 7) The VPA dose of stead-state was highest under 1 year (monotherapy: 24.8mg/kg/day, polytherapy: 33.4mg/kg/day). The VPA dose decreased in accordance with an increase of the age. 8) There was no correlation between EEG change and plasma concentration of VPA. 9) There was linear correlation between clinical affect and plasma VPA level, and plasma concentration of VPA reached 51 to 100microgram/ml at that time. 10) The clinical effect was good in abscence seizure, simple partial seizure, myoclonic seizure, and generalized tonic clonic seizure in decreasing order. 11) The incidence of side effect were gastrointestinal disturbance, behavior disorder, laboratory abnormality, neurologic abnormality in order of frequency. The frequency of overall side effects observed was 40% but toxic effects were generally mild.
Child* ; Chungcheongnam-do ; Daejeon ; Electroencephalography ; Epilepsy ; Female ; Humans ; Incidence ; Male ; Plasma ; Seizures ; Valproic Acid*

This study investigated the stress of community residents in Kwang-Ju and Chonnam areas by using the General Health Questionnaire(GHQ-60) as a instrument of stress measurement. The number of subject were 445 residents who lived in three areas (large city, middle city, and rural area) and they were individually interviewed in March, 1994. The result of study showed that the degrees of stress measured by GHQ-60 were statistically significant in the residents' area, age. sex variables: (a) the residents in middle city among three area had the highest level of stress: (b) the resident who were more than 60 in age had the highest level of stress: (c) the female resident had more stress than male residents: (d) particularly, the residents who were more than 60 years old in the middle city had the highest level of stress. Further, the results of factor analysis showed that there were three factors of social dysfunction, depression and anxiety, and psychosomatic symptom. The social dysfunction factor was statistically significant in both age and resident area variables. The depression and anxiety factor was statistically significant in the residents' area, age. sex variables. The psychosomatic symptom factor was statistically significant in both age and sex variables. The study suggested that they should give a special attention to solve the old people's stress because stress was closely related to residents age.
Anxiety ; Depression ; Factor Analysis, Statistical ; Female ; Gwangju ; Humans ; Jeollanam-do ; Male ; Mass Screening* ; Middle Aged ; Surveys and Questionnaires*

No abstract available.

No abstract available.
Fracture Fixation, Intramedullary*

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is a chronic inflammatory disorder that significantly diminishes the quality of life of patients.Current pharmacological treatments are often limited by low therapeutic efficacy and severe side effects, restricting their long-term application. This necessitates the development of novel therapeutic strategies. Exosome-based therapies have recently emerged as promising candidates due to the therapeutic potential demonstrated by exosomes derived from mammalian cells and plant sources in IBD management. These exosomes exhibit antiinflammatory effects by downregulating proinflammatory cytokine expression, modulating macrophage polarization, and promoting mucosal regeneration. However, scalability challenges and high production costs hinder the clinical translation of mammalian cell-derived exosomes. In contrast, plant-derived exosomes offer distinct advantages, including cost-effective large-scale production, enhanced stability, and reduced immunogenicity, positioning them as a emerging next-generation therapeutic modality for IBD. However, there are still some hurdles in the standardization of largescale exosome production and the precise elucidation of their therapeutic mechanisms. Future research needs to focus on optimizing exosome manufacturing processes, conducting mechanistic studies, and combinatory approaches to accelerate clinical application.

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is a chronic inflammatory disorder that significantly diminishes the quality of life of patients.Current pharmacological treatments are often limited by low therapeutic efficacy and severe side effects, restricting their long-term application. This necessitates the development of novel therapeutic strategies. Exosome-based therapies have recently emerged as promising candidates due to the therapeutic potential demonstrated by exosomes derived from mammalian cells and plant sources in IBD management. These exosomes exhibit antiinflammatory effects by downregulating proinflammatory cytokine expression, modulating macrophage polarization, and promoting mucosal regeneration. However, scalability challenges and high production costs hinder the clinical translation of mammalian cell-derived exosomes. In contrast, plant-derived exosomes offer distinct advantages, including cost-effective large-scale production, enhanced stability, and reduced immunogenicity, positioning them as a emerging next-generation therapeutic modality for IBD. However, there are still some hurdles in the standardization of largescale exosome production and the precise elucidation of their therapeutic mechanisms. Future research needs to focus on optimizing exosome manufacturing processes, conducting mechanistic studies, and combinatory approaches to accelerate clinical application.

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is a chronic inflammatory disorder that significantly diminishes the quality of life of patients.Current pharmacological treatments are often limited by low therapeutic efficacy and severe side effects, restricting their long-term application. This necessitates the development of novel therapeutic strategies. Exosome-based therapies have recently emerged as promising candidates due to the therapeutic potential demonstrated by exosomes derived from mammalian cells and plant sources in IBD management. These exosomes exhibit antiinflammatory effects by downregulating proinflammatory cytokine expression, modulating macrophage polarization, and promoting mucosal regeneration. However, scalability challenges and high production costs hinder the clinical translation of mammalian cell-derived exosomes. In contrast, plant-derived exosomes offer distinct advantages, including cost-effective large-scale production, enhanced stability, and reduced immunogenicity, positioning them as a emerging next-generation therapeutic modality for IBD. However, there are still some hurdles in the standardization of largescale exosome production and the precise elucidation of their therapeutic mechanisms. Future research needs to focus on optimizing exosome manufacturing processes, conducting mechanistic studies, and combinatory approaches to accelerate clinical application.

BACKGROUND: We evaluated the current status of diabetes management and the predictors for poor glycemic control in an urban area. METHODS: This study included 1,138 community-dwelling adults (> or =50 years) with diabetes, of which 584 participated in the diabetes care survey. Logistic regression was used to identify the factors predicting poor glycemic control (hemoglobin A1c[HbA1c]> or =7%) in the total sample and to evaluate the relationship between the history of diabetes management checkup and poor glycemic control in the diabetes care survey sample. RESULTS: Of the 1,138 patients, 53.2% had blood pressure less than 130/80 mmHg, 41.7% had fasting glucose between 70 and 130 mg/dL, 48.6% had HbA1c below 7.0%, 60.1% had triglycerides below 150 mg/dL, 41.4% had low density lipoprotein cholesterol below 100 mg/dL, and 59.1% had normoalbuminuria (urine albumin-to-creatinine ratio <30 mg/g creatinine). Of the 584 patients completing the diabetes care survey, 63.9% had one or more lipid tests, 32.0% had one or more HbA1c tests, 43.8% had one or more microalbuminuria tests, and 42.5% had one or more fundoscopic examinations annually. Female gender (odds ratio [OR], 1.71; 95% confidence interval [CI], 1.23-2.36), duration of diabetes (OR, 1.07; 95% CI, 1.06-1.09), and alcohol use (OR, 1.40; 95% CI, 1.06-1.85) were associated with an increased risk for poor glycemic control while age (OR, 0.97; 95% CI, 0.96-0.99) and antihypertensive medication (OR, 0.64; 95% CI, 0.50-0.83) were associated with a decreased risk. CONCLUSIONS: This study shows that glycemic control is likely to be poor in urban areas. We need to develop appropriate community-based strategies to achieve optimal glycemic control and prevent diabetes complications.
Adult ; Blood Pressure ; Cholesterol ; Cholesterol, LDL ; Diabetes Complications ; Diabetes Mellitus ; Fasting ; Female ; Glucose ; Hemoglobin A, Glycosylated ; Humans ; Lipoproteins ; Logistic Models ; Triglycerides

No abstract available.
Iron* ; Skin Pigmentation*

No abstract available.
Anemia ; Gaucher Disease* ; Humans ; Siblings* ; Thrombocytopenia